SCHEMBL6925569

SCHEMBL6925569

CCCON1C(=O)c2cccc(Oc3cc(C)cc(OS(=O)(=O)c4ccccc4S(=O)(=O)N4CCN(C(=O)OCC)CC4)c3)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 4/20 0.41
TSHR P16473 3/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
F2 P00734 6/20 0.40
F10 P00742 1/20 0.40
PRSS2 P07478 1/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
MAPT P10636 2/20 0.39
HSD17B10 Q99714 1/20 0.38
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7649155 0.90 MEN1 (0.39) ALDH1A1SMN1; SMN2TSHRF2F10
SCHEMBL6926975 0.85 F2 (0.37) ALDH1A1KDM4EGAAF2F10
SCHEMBL6749785 0.84 F2 (0.47) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL6930340 0.77 TSHR (0.45) ALDH1A1SMN1; SMN2TSHRKDM4EHPGD
SCHEMBL6749786 0.77 F2 (0.44) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL6925571 0.77 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL6747717 0.77 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2LMNAHTTF2
SCHEMBL7649302 0.75 F2 (0.46) ALDH1A1SMN1; SMN2LMNATSHRHTT
SCHEMBL6750147 0.74 F2 (0.53) ALDH1A1SMN1; SMN2LMNATSHRHTT
Hydrochloric Acid SCHEMBL7650990 0.74 F2 (0.46) ALDH1A1SMN1; SMN2LMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518310-B2 Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-02-11 US disclosed
EP-0944590-B1 AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 2002-03-20 EP disclosed
US-20010037039-A1 Aminoguanidines and alkoxyguanidines as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037039-A1 Aminoguanidines and alkoxyguanidines as protease inhibitors F9, PLG, MMP9 ALDH1A1 3151/4885SMN1; SMN2 3532/4885LMNA 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.